AcrannoLife Genomics

Executive Summary

AcrannoLife Genomics is an Indian precision diagnostics company leveraging a proprietary molecular counting platform for non-invasive liquid biopsy tests. Its flagship Trunome test analyzes cell-free DNA for early detection and monitoring of chronic diseases, organ transplant health, and infectious diseases like COVID-19. The company also developed COVIQWIK, a rapid RT-LAMP kit for viral detection. Founded in 2020 and based in Hyderabad, AcrannoLife has raised $5M and is at a commercial stage, targeting the growing Indian diagnostics market with a focus on affordability and accessibility. The company's platform holds potential for broad clinical utility, though it faces competition from established players. AcrannoLife's near-term growth hinges on expanding clinical validation, securing hospital partnerships, and scaling manufacturing. With increasing demand for non-invasive diagnostics in India and globally, the company is well-positioned to capture market share. Key risks include regulatory hurdles and adoption rates. Overall, AcrannoLife represents a promising but early-stage opportunity in precision medicine.

Upcoming Catalysts (preview)

• Q3 2026Launch of Trunome test for new chronic disease indications70% success
• Q4 2026Strategic partnership with major hospital chain in India60% success
• Q2 2026Series A funding round to accelerate commercialization75% success